1
|
Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS One 2015; 10:e0139650. [PMID: 26406908 PMCID: PMC4583491 DOI: 10.1371/journal.pone.0139650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
2
|
Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS One 2015; 10:e0136731. [PMID: 26340098 PMCID: PMC4560419 DOI: 10.1371/journal.pone.0136731] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2015] [Accepted: 08/08/2015] [Indexed: 01/03/2023] Open
Abstract
Background The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy and the outcome of patients. Methods Data of consecutive patients who underwent surgery from January 2007 to December 2012 for HER2-positive, pT1a-b pN0 M0 breast cancer were retrospectively collected from 28 Italian centres. Analysis of contingency tables and multivariate generalized logit models were used to investigate the association between the baseline clinical and biological features and the treatment strategy adopted. Results Among 303 enrolled patients, 204 received adjuvant systemic therapy with trastuzumab, 65 adjuvant systemic therapy without trastuzumab and 34 did not receive adjuvant systemic therapy. At the multivariate analysis age, tumor size, proliferation index and hormone receptor status were significantly associated with the treatment choice. Five-year disease-free survival (DFS) probability was 95%, 94.3% and 69.6% for patients treated with adjuvant systemic therapy and trastuzumab, with adjuvant systemic therapy without trastuzumab and for patients who did not receive adjuvant systemic therapy, respectively (p<0.001). Conclusions The majority of patients (66%) with pT1a-b pN0 HER2-positive breast cancer enrolled in this retrospective study received adjuvant systemic therapy with trastuzumab, whereas only 11% patients did not receive any adjuvant systemic therapy. The choice of treatment type seems to be mainly influenced by tumor size, proliferation index, hormone receptor status and age. The 5-year DFS probability was significantly higher for patients receiving adjuvant systemic therapy with trastuzumab compared with patients not receiving adjuvant systemic therapy or receiving adjuvant systemic therapy without trastuzumab.
Collapse
MESH Headings
- Adjuvants, Pharmaceutic/therapeutic use
- Adult
- Age Factors
- Aged
- Antineoplastic Agents/therapeutic use
- Breast Neoplasms/diagnosis
- Breast Neoplasms/drug therapy
- Breast Neoplasms/mortality
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/surgery
- Chemotherapy, Adjuvant
- Disease Management
- Female
- Gene Expression
- Humans
- Middle Aged
- Multivariate Analysis
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Prognosis
- Receptor, ErbB-2/genetics
- Receptor, ErbB-2/metabolism
- Retrospective Studies
- Survival Analysis
- Trastuzumab/therapeutic use
- Tumor Burden
Collapse
Affiliation(s)
- Stefania Gori
- Department of Oncology, Ospedale Sacro Cuore don Calabria, Negrar–Verona, Italy
- * E-mail:
| | - Alessandro Inno
- Department of Oncology, Ospedale Sacro Cuore don Calabria, Negrar–Verona, Italy
| | - Elena Fiorio
- Unit of Oncology, Ospedale Civile Maggiore, Verona, Italy
| | | | | | | | - Graziella Pinotti
- Department of Oncology, Ospedale di Circolo and University of Insubria, Varese, Italy
| | - Marta Gubiotti
- Medical Oncology, Ospedale Civile di Macerata, Macerata, Italy
| | | | - Monica Turazza
- Department of Oncology, Ospedale Sacro Cuore don Calabria, Negrar–Verona, Italy
| | - Simona Duranti
- Department of Oncology, Ospedale Sacro Cuore don Calabria, Negrar–Verona, Italy
| | | | - Laura Iezzi
- Medical Oncology, Ospedale SS Annunziata, Chieti, Italy
| | - Giancarlo Bisagni
- Medical Oncology, Breast Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | - Simon Spazzapan
- Medical Oncology, C.R.O.–I.R.C.C.S., Aviano–Pordenone, Italy
| | - Luigi Cavanna
- Department of Oncology and Hematology, Ospedale Guglielmo da Saliceto, Piacenza, Italy
| | - Chiara Saggia
- Medical Oncology, Ospedale Maggiore della Carità, Novara, Italy
| | - Emilio Bria
- Department of Medicine, Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | | | - Patrizia Vici
- Division of Medical Oncology B, Regina Elena National Cancer Institute, Roma, Italy
| | - Daniele Santini
- Department of Medical Oncology, Campus Bio-Medico University, Roma, Italy
| | - Alessandra Fabi
- Division of Medical Oncology A, Regina Elena National Cancer Institute, Roma, Italy
| | - Ornella Garrone
- Division of Medical Oncology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
| | | | - Laura Amaducci
- Medical Oncology, Ospedale per gli Infermi, Faenza–Ravenna, Italy
| | | | | | - Sandro Barni
- Medical Oncology, Azienda Ospedaliera Treviglio, Treviglio–Bergamo, Italy
| | | | | | - Lucio Laudadio
- Department of Oncology, Ospedale Floraspe Renzetti, Lanciano–Chieti, Italy
| | - Alessandra Zoboli
- Medical Oncology, Ospedale San Sebastiano, Correggio–Reggio Emilia, Italy
| | - Fabiana Marchetti
- Department of Oncology, Ospedale Sacro Cuore don Calabria, Negrar–Verona, Italy
| | - Giuseppe Bogina
- Pathology, Ospedale Sacro Cuore don Calabria, Negrar–Verona, Italy
| | - Gianluigi Lunardi
- Department of Oncology, Ospedale Sacro Cuore don Calabria, Negrar–Verona, Italy
| | - Luca Boni
- Azienda Ospedaliero–Universitaria Careggi, Firenze, Italy
| |
Collapse
|